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Summary.-Sera from patients with nasopharyngeal carcinoma (NPC), a disease
associated with Epstein-Barr virus (EBV), were found to be cytotoxic at 15°C in
the presence of complement for a panel of human lymphocytes, with a higher fre-
quency than those of matched controls. The cold lymphocytotoxic antibodies
(LTA) responsible for this activity have the same properties as those described in
sera from individuals with acute viral infections. The frequency and geometric
mean titres (GMT) of LTA varied with the origin of the patient (Chinese > North
African > Caucasian) and the stage of the disease (Stage IV > Stage I). A positive
correlation between LTA and anti-EBV titres was found with regard to antibodies
to the viral capsid antigen (VCA) and the EBV-specified nuclear antigen (EBNA).
The absence of correlation between LTA and anti-early antigen (EA) titres probably
reflects the complex relationships existing between viral infection and LTA pro-
duction, but is compatible with the hypothesis that LTA acts as an immune regula-
tory mechanism in viral infections.
CYTOTOXIC activity against a panel
of human lymphocytes, complement-de-
pendent and optimal at 15°C, was describ-
ed by Mottironi and Terasaki in patients
with acute viral infections such as in-
fectiousmononucleosis,rubellaandmeasles
(Mottironi and Terasaki, 1970). This
low-avidity antibody, known as cold
lymphocytotoxic antibody (LTA), was
later found in various pathological condi-
tions, including systemic lupus erythe-
matosus (SLE) (Terasaki, Mottironi and
Barnett, 1970; Mittal et al., 1970; Ooi et
al., 1974; Winchester et al., 1974), parasitic
infections (Mayer, Falkenrodt and Tongio,
1973) and pernicious anaemia (Goldberg,
Cunningham and Terasaki, 1972). In
SLE patients, the presence of LTA was
found to correlate with that of antibodies
to native DNA and single-stranded RNA
(DeHoratius et al., 1975).
Correspondence to: J.-P. Lamelin.
Nasopharyngeal carcinoma (NPC) oc-
curs with high frequency among Southern
Chinese, with intermediate frequency in
North and East African populations and
low frequency among Caucasians (Ho,
1972). This tumour is associated with
infection by Epstein-Barr virus (EBV)
(reviewed by de-The, Ho and Muir, 1976),
the causative agent of infectious mono-
nucleosis (IM) and, at least among the
high-risk group of Southern Chinese, is
linked with a characteristic HLA haplo-
type (Simons et al., 1975b). Because of
this association between NPC and EBV,
we have examined whether LTA was
produced in the patients with NPC, as
it is in IM patients.
In the study reported here, sera from
NPC cases and control individuals ob-
tained from each of the 3 geographical
areas were examined for the presenceCYTOTOXIC ANTIBODIES IN NASOPHARYNGEAL CA
and titres of LTA and anti-EBV anti-
bodies. It will be shown that: (1) LTA
is present with higher frequency and at
higher titres in sera from NPC patients
than in the control sera; (2) both geo-
graphical origin and the stage of the
disease influence the production of LTA;
and (3) a positive correlation exists
between LTA and anti-EBV titres in
NPC sera.
MATERIALS AND METHODS
Tests and control sera.-Ninety-eight sera
from patients with NPC, diagnosed in Hong
Kong (43), Tunis (42) and Paris (13) were
selected so that the various stages of the
disease (Ho, 1970) were statistically equally
distributed among the 3 groups. Control
groups in each area consisted of age-matched
normal individuals.
Preparation oflymphocytes.-Heparinized,
pre-warmed (37°C) blood from normal Cau-
casian donors was passed through a nylon
fibre column (Rhodiaceta TD3, Roger Bellon,
Neuilly, France; 5 g/20 ml of blood) at a
rate of 2-4 ml/min. The eluate was thor-
oughly mixed with dextran (6 X 105 mol.
wt.; 0-5% final) and left at room temperature
for 20 min. The lymphocyte-rich upper
fraction was cleared of contaminating ery-
throcytes by 0 85% NH4C1 treatment, centri-
fuged, washed once at 4°C and resuspended
in RPMI 1640. This selected population,
90-95%o T lymphocytes, was 98-990/ viable.
The final suspension was adjusted to 2 X 106
cells/ml.
Complement. A pool of rabbit sera,
selected for its lack of cytotoxicity toward
human lymphocytes and kept frozen at
-60°C, was used as the source of comple-
ment.
Cytotoxicity assay.-The cytotoxicity of
each test serum against a panel of 10 normal
lymphocyte populations was evaluated under
oil in Terasaki microplates, as described by
Mottironi and Terasaki (1970), with minor
modifications. In brief, 1 ,ul of the test sera
(serially diluted up to 1: 16) were mixed
with 1 ,u cell suspension (i.e. 2000 cells).
After 30 min at 4°C, 4 pi of rabbit serum
was added and the mixture left for 31 h at
15°C. Following the addition of 2 ,A 500
eosin and 5 yd 400o formaldehyde (pH 7.2),
the percentage of dead cells was scored as
follows: 0-20% = negative; 20-40% +;
40-60% = ++; 60-80% - +++; 80-
100% = ++++. Controls included nega-
tive and positive sera.
For each test serum, 3 additional assays
were run in parallel: one at 37°C, the others
at 15°C and 37°C in the presence of an equal
volume of0-01 M dithiotreitol (DTT), a reduc-
ing agentknown to abrogateIgM, but notIgG,
antibody activity. The cytotoxicity of sera
containing anti-HLA activity was noted at
37°C, resistant to DTT treatment, and
usually restricted to a small number of cell
suspensions from the panel. In contrast,
LTA-containing sera were cytotoxic at
15°C, but not at 37°C, sensitive to DTT
treatment, and killed all or most cell
suspensions.
Expression of the results.-A serum was
considered positive when there were >20%
dead cells in at least 2 lymphocyte suspen-
sions of the panel. With most of the
positive sera, this activity could be titrated
by dilution. As these dilutions were different
for the various suspensions of the panel,
the geometric mean titre (GMT) of the
last dilutions giving 20% or more dead
cells was calculated, and taken as the LTA
titre of the serum.
EBV serology.-Antibodies against viral
capsid antigen (VCA) and early antigen (EA)
were titrated by the indirect immuno-
fluorescence technique as described by
Henle (Henle and Henle, 1966; Henle et
al., 1970b). The anticomplement immuno-
fluorescence test of Reedman and Klein
(1973) was used to determine the activity
against Epstein-Barr nuclear antigen
(EBNA).
Statistics. Percentage ofindividuals with
LTA was compared between various groups
by the x2 test. The GMT of positive sera
within each group was determined and
compared by Student's t test.
RESULTS
1. LTA in NPC and controlsfrom different
geographical areas (Table I)
In all results reported below, the
cytotoxic activity of LTA+ sera was
shown to be complement-dependent and,
in agreement with the postulated IgM
nature of the antibodies (Chalopin et
al., 1975), DTT-sensitive. The absorp-
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TABLE I. Percentage ofSera with LTA Activity and GMT ofPositive Sera in NPC and
Control Groupsfrom Different Geographical Areas
% LTA+*
NPC Controls
Chinese 84 (36/43) 28 (8/29
Tunisians 64 (27/42) 64 (9/14
Caucasians 62 (8/13) 17 (10/6
* No. positive/no. tested in parentheses.
t N.S. = not, significant.
<0*0005
N.S.t
<0-001
0)
GMT (transformed standarct error, tse)
NPC Controls P
3-2 (1-17) 1-2 (1-12) <0-01
2 - 4 (41 17) 1 * 3 (1*10) <0*01
1-7 (1-19) 1-1 (1.09) <0 05
TABLE II.-Percentage of LTA+ Sera and GMT ofPositive Sera in NPC Patientsfrom
Hong Kong at Different Stages of the Disease
% LTA+ A(NPC-C)* GMT (tse) A(NPC-C)
Controls 28 (8/29) 1-19 (1-37)
Stage 1+11 71 (10/14) <0-01 2 0 (1 30) <N.S.
Stage III 93 (13/14) <0-001 3-03 (1-30) <0 05
Stage IV 87 (13/15) <0-001 4-92 (1-28) <0 01
* Level of significance (P value) of the difference between NPC andl control groups.
tion of a few highly positive sera with
platelets, polymorphonuclear cells and
EBV-positive B lymphoblastoid cells (Line
4091) has no effect, in contrast to the
loss of cytotoxicity after absorption with
T lymphocytes. Finally, the observa-
tions that sera with a titre >4 were
cytotoxic for >80% of the cells in all
of the lymphocyte suspensions from the
panel indicated that the specificity was
not restricted to a small subset of T cells.
The frequency of LTA+ sera, as well
as the GMT of these positive sera, was
higher in the NPC than in the control
groups, for both Caucasians (620/o v
17% and 1-7 vs 141 respectively) and
Chinese (84% vs 28% and 3'2 vs 1.2
respectively). The frequency of LTA+
sera was identical (64%) in Tunisian NPC
cases and controls, although their GMT
was higher in the NPC than in the control
group (2.4 vs 1-3; P < 0 01). Finally,
when the GMTs of LTA+ NPC sera from
different geographical areas were com-
pared, they ranged from I P7 for Caucasians
to 2-4 for Tunisians and 3-2 for Chinese:
the difference between Caucasians and
Chinese is significant (P < 0*01).
2. LTA in NPC at different stages of the
disease (Table II)
As the criterion for determining the
stage of the disease was slightly different
in Hong Kong than in the other areas,
comparison was first made between dif-
ferent stages (I + II, III and IV) among
the homogeneous Chinese group. The
frequency of LTA+ sera was similar in
the 3 groups. However, when their
GMTs were compared, they were found to
increase steadily with the stage (2-0;
3 0; 449). These 2 last values were
significantly higher (P<0 05 and P<0 01,
respectively) than the GMT of positive
control sera.
The comparison between stages, ir-
respective of the geographical origin of
the patients, resulted in difficulties, owing
to slight differences in the criteria used
for staging and to different levels of LTA
between groups ofNPC patients according
to their origin (see above). Despite this
increased heterogeneity in the sampling,
the difference in LTA between Stages
(I + II) and IV was still significant
(Table III).
3. LTA and anti-EBV antibodies in lNPC
patients (Table IV)
All NPC sera were examined for
the presence and titre ofantibodies against
the VCA of EBV. A positive correlation
between titres of LTA and of anti-VCA
antibodies was found in the Chinese
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TABLE III. Percentage of LTA+ Sera and GMT of Positive Sera among NPC Patients
and Control Groups, at Different Stages of the Disease, Irrespective of Geographical
Origin
Stage % LTA+ A(NPC -C)* GMT (tse) A(NPC -C)
Controls 28 (27/96) 1-28 (1-08)
1+11 60 (12/20) <0.01 2-25 (1-23) N.S.
III 73 (16/22) <0 0005 3.-07 (1-28) <0-001
IV 81 (42/52) <0-0005 3 03 (1-15) <0-001
* Level of significance (P value) of the (lifference between the NPC an(l control groups.
TABLE IV.- Association between LTA and Anti-EBV Titres (Anti-VCA,
Anti-EBNA and Anti-EA)
Anti-VCA
r* P
Chinese 0*31 <0*05
(43)t
Tunisians 0 * 33 <0*05
(38)
Caucasians 0* 50 N.S.
(1:3)
Anti-EBNA
r P
0* 53 <0(01
(27)
N.D.
Anti-EA
r P
N.D.
-0-08 N.S.
(26)
0-41 N.S.
(13)
* Correlation coefficient with LTA.
t Numbers ofNPC cases in parentheses.
+ N.D. = Not done.
(r 0 33; P < 0-05) and in the Tunisian
(r 0-31; P < 0.05) groups. In
addition, 27 NPC sera from Tunis
were also tested for the presence of
anti-EBNA antibodies. A strong positive
correlation (r 0 53; P < 0.01) between
titres of these antibodies and LTA was
again found. In contrast, no correlation
was found between LTA and anti-EA
titres within the group of 26 Tunisian
NPC cases examined.
DISCUSSION
We have examined the presence of
LTA and their GMT in sera from patients
with NPC, a tumour associated with
EBV. First evidence for this association
came from serological data showing that
anti-EBV antibody titres are higher in
NPC cases than in matched controls
(Old et al., 1966; Henle et al., 1970a;
De Schryver et al., 1969; de-The et al.,
1975). That this might correspond to
an increase in the antigenic load is
supported by the frequent appearance,
during NPC evolution, of antibodies
directed against EBV early antigens
(Henle, 1971). Further indication that
EBV was associated with NPC came
from the discovery that its genome is
present in the malignant epithelial cells
(Wolf, zur Hausen and Becker, 1973;
Desgranges et al., 1975). Besides its
association with EBV, NPC has a geo-
graphical distribution characterized by
a high frequency among Cantonese Chin-
ese, and low frequency among Caucasians,
the frequency among North African popu-
lations being intermediate. The high
risk is attributable, at least partly, to
some genetically determined factor which
might be of immunological nature (Simons
et al., 1975a). Thus among Southern
Chinese the high risk has conclusively
been shown to be associated with the
specific HLA-A2, B Sin2haplotype (Simons
et al., 1975a).
LTA is known to be produced during
the acute phase ofvarious viral infections,
where it might represent some non-
specific by-product of the antibody re-
sponse, either against virus-modified cell
membranes or against structures charac-
teristic of cells from the stimulated
clones, thus reflecting some operating
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regulatory processes. As there is a sug-
gestionthat EBV might be " reactivated "
in NPC patients, resulting in high titres
of specific anti-EBV antibody, it was
interesting to examine the production
of LTA in those circumstances.
Our results show that the incidence
and GMT of LTA+ sera is higher among
NPC patients than among controls in
the Chinese and the Caucasian groups.
In the North African group, the incidence
of LTA was as high among matched
controls as among NPC patients. This
high frequency of LTA in the normal
population was confirmed when sera
from " healthy " Tunisian students were
examined. Fifty-five per cent (17/31)
were LTA+, but again their GMT was
low (1.4). The reason for this " high
background " of LTA was not due to
any technical or sampling problem and
remains unclear. The possible role of
parasitic infestations (Mayer et al., 1973)
could not be assessed in this unexpected
observation.
When the frequencies and levels of
LTA in NPC patients from different
geographical areas were compared, the
highest values were found in the Chinese
group, the lowest in the Caucasian group.
This parallels the risk for NPC in these
different areas. The difference in GMT,
significant at the 1% level between
Chinese and Caucasian LTA+ sera, did
not result from an unequal distribution
of stages between the geographically
determined samples, did not reflect dif-
ferent levels of LTA in the corresponding
normal populations, but likewise parallels
the incidence of NPC in the different
geographical areas.
An interesting observation was that
the GMT of LTA among NPC patients
rose with tumour progression. This could
not be ascribed to therapy, since all
patients in these series were bled prior
to treatment. The tumour burden is
not, however, a sufficient condition for
inducing LTA production. That the pre-
sence of LTA is not an obligatory side-
effect of tumour development, is illus-
trated by the follow-up of a Caucasian
population of 75 breast cancers: 17 (23%)
were positive as compared to 8 out of
40 (20%) in the age-sex matched control
population. These percentages remained
stable during and following cobalto-
therapy (up to 3 months) (Revillard et
al., unpublished).
In contrast, a high incidence and
high GMT of LTA were found in a series
of 15 Ugandan patients with Burkitt's
lymphoma (BL) (a second EBV-associated
tumour). The unexpected finding that
they did not differ significantly from
that of 14 controls, prevented any inter-
pretation. Here again the picture might
have been obscured by the heavy parasitic
infection (Mayer et al., 1973) in tropical
areas.
Most associations of LTA with patho-
logical situations have been found with
acute viral infections, including the EBV-
caused IM (Mottironi and Terasaki, 1970),
or diseases in which the role of a virus
is suspected (Terasaki et at., 1970; Mittal
et al., 1970; Ooi et al., 1974; Winchester et
al., 1974). The best studied example
is SLE, where a correlation between the
finding of LTA and anti-nuclear anti-
bodies has been reported (DeHoratius et
al., 1975). A representative sample of
the sera entered in this LTA study is
now analysed for anti-nuclear factors,
another antibody activity described in
sera from NPC cases (see below). Our
finding of a positive correlation between
titres of anti-VCA antibody and LTA
and, among Tunisians (the only group
studied) between anti-EBNA antibody
and LTA, supports the interpretation
that LTA and active viral infections
have a close relationship. The failure
to find a correlation between anti-EA
(a marker of EBV-replication) and LTA
titres might be only an apparent paradox.
This is, indeed, the kind ofresult expected
when two parameters, linked by a feed-
back mechanism, are compared without
taking into account the onset of the
regulatory mechanism.
An interesting control group would
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be normal individuals with a high anti-
EBV reactivity. This is, however, un-
realistic, since such a high reactivity is
characteristic of IM, NPC and BL, all
circumstances in which LTA is indeed
produced.
Finally, it is tempting to speculate
on the possible relationship between NPC
and LTA. The development of an NPC
tumour probably results from multi-
factorial events in which EBV and
genetic factor(s) may play important
roles.
In addition to the observations men-
tioned above, the existence of a link,
in a given geographical area, between
the incidence of NPC and the proportion
of NPC with high LTA titres, indirectly
supports the hypothesis that EBV plays
a role in NPC. If, indeed, EBV reactiva-
tion is one of the single events (or a
co-factor) increasing the probability at
which NPC occurs and is, at the same
time, responsible for LTA production,
then a difference in the frequency of
this reactivation is expected to result in
parallel variations on both the incidence
of NPC in the general population and
the level of LTA in these patients.
As to the possible role of genetic
factors, it rests on the discovery by
Simons et al. (1975a) of an association,
among Singapore Chinese, between NPC
and the specific A 2, B Sin2, HLA haplo-
type. The association of NPC with a
given major histocompatibility complex
(MHC) haplotype suggests the existence
in this disease, as in many others (Moller,
1975), ofanMHC-specific " disease suscep-
tibility gene " (McDevitt and Bodmer,
1974). Furthermore, the finding in Chin-
ese patients with NPC of hyporesponsive-
ness in vivo to purified protein derivative
and in vitro to phytohaemagglutinin
(Chan et al., 1976), as well as the high
incidence of antinuclear factors (Yoshida,
1971; Yoshida, Yasuda-Yasaki and Ut-
sumi, 1975) is consistent with an immuno-
logic component in the pathogenesis of
NPC, and raises the possibility that the
" disease susceptibility gene " may exert
its function by regulating immune re-
sponsiveness. The ability to develop
LTA, an antibody with specificity mainly
restricted to T lymphocytes (Lies, Messner
and Williams, 1973), might represent
another facet of this genetically deter-
mined " susceptibility ". The compari-
son, in frequency and GMT, of LTA+
sera between individuals with and without
the haplotype associated with high risk
for NPC might provide some clue for
testing this hypothesis.
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